Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HRD Positive Advanced Ovarian Cancer”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Looking for participantsNCT07033819
What this trial is testing

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Who this might be right for
Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 48
Large-scale testing (Phase 3)Looking for participantsNCT07318558
What this trial is testing

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Who this might be right for
Ovarian NeoplasmsOvarian Cancer
Merck Sharp & Dohme LLC 900
Testing effectiveness (Phase 2)Looking for participantsNCT07667751
What this trial is testing

An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer

Who this might be right for
Ovary Cancer
Bai-Rong Xia 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07647653
What this trial is testing

Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Shandong University 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07652073
What this trial is testing

DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

Who this might be right for
Advanced or Metastatic Ovarian Cancer
Danatlas Pharmaceuticals Co., Ltd 30
Large-scale testing (Phase 3)Looking for participantsNCT07776691
What this trial is testing

Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

Who this might be right for
Ovarian CancerOvarian NeoplasmsPeritoneal Cancer+1 more
Merck Sharp & Dohme LLC 802
Large-scale testing (Phase 3)Looking for participantsNCT06954584
What this trial is testing

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

Who this might be right for
Ovarian Cancer
Tongji Hospital 424
Large-scale testing (Phase 3)Active Not RecruitingNCT02655016
What this trial is testing

Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 733
Testing effectiveness (Phase 2)Looking for participantsNCT06141265
What this trial is testing

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

Who this might be right for
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Peking University Cancer Hospital & Institute 116
Testing effectiveness (Phase 2)Study completedNCT04417192
What this trial is testing

Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

Who this might be right for
Ovarian Cancer
National Cancer Center Hospital East 30
Testing effectiveness (Phase 2)Ended earlyNCT06065059
What this trial is testing

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Who this might be right for
Breast CancerOvarian CancerPancreas Cancer+5 more
Tango Therapeutics, Inc. 7